NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
The National Center for Natural Products Research has applied to register as an importer of basic classes of controlled substances.
The application was published by the Drug Enforcement Administration on 19 October 2026. The public comment period ends on 18 November 2026, with further drug information provided in supplementary material.
Janssen Pharmaceuticals, Inc. has applied to register as a bulk manufacturer of basic classes of controlled substances.
Janssen Pharmaceuticals, Inc. has applied for registration as a bulk manufacturer of basic classes of controlled substances. The application includes a comment period ending on 18 December 2026.
Groff Health Inc has applied to register as a bulk manufacturer of basic classes of controlled substances.
The Drug Enforcement Administration published notice of Groff Health Inc’s application on 19 October 2026. Comments are due by 18 December 2026.
Halo Pharmaceutical Inc. has applied to import Schedule I psilocybin for formulation development and clinical trials, with public comments due by 18 November 2026.
Halo Pharmaceutical Inc., based in Whippany, New Jersey, applied to register as an importer of psilocybin, drug code 7437. Any authorisation would be limited to the specified basic class and would not cover FDA-approv...
Magic mushroom ingredient takes the fight out of aggressive fish
A psychedelic compound found in magic mushrooms appears to have an unexpected effect: calming highly aggressive fish. Researchers discovered that low doses of psilocybin significantly reduced aggressive attacks in man...
A Swedish randomised trial found that one 25 mg dose of psilocybin reduced depression within days, but its clinician-rated advantage over niacin placebo was no longer significant after a year.
The trial involved 35 adults with moderate-to-severe recurrent major depressive disorder, all of whom received five psychotherapeutic support sessions. Psilocybin improved clinician-rated symptoms more than 100 mg nia...
What if post-psychedelic difficulties are sometimes forms of health anxiety?
When fear of harm might actually sustain the harm
Researchers go undercover to study Oregon’s psilocybin centers; Are psychedelic treatments leaving behind therapy?
Plus: Iowaska Church makes a deal with DEA; Do music playlists in psilocybin trials rise and fall with participants’ trips?
Vital Community Webinar
This Vital Community webinar introduces an emerging sub-threshold psilocybin protocol developed within a trauma-informed, parts-based therapeutic framework. This approach adapts the principles of low-dose psychedelic ...
Tony Soprano Took Peyote & Felt Better About Murder
Welcome to The Psychedelic Blog. A bestselling publication exploring altered states & the culture surrounding them.
Can VR Really Recreate a Psychedelic Trip?
This writer says yes ... well, almost. [...] Read More...
Context Shapes Alpha-Band Electrophysiological Signatures Under Psilocybin
This EEG preprint compared baseline with 19 mg oral psilocybin in healthy adults (n=56 for rest, meditation and music; n=53 for movie viewing). Alpha power and connectivity generally fell at rest, while structured con...
Real-world clinical outcomes under intravenous and subcutaneous esketamine protocols for treatment-resistant depression: a multicenter, retrospective study
This retrospective multicentre study (n=72) compared intravenous and subcutaneous esketamine protocols for treatment-resistant depression in routine clinical care. Intravenous treatment showed a more favourable respon...
Serotonergic psychedelics delay resting state neurovascular coupling dynamics
This brain imaging analysis (s=2, n=32) found that LSD and DMT slowed blood-flow responses in brain regions linked to serotonin receptors during rest. Correcting for these vascular effects improved detection of drug-r...
Real-world clinical outcomes under intravenous and subcutaneous esketamine protocols for treatment-resistant depression: a multicenter, retrospective study
This retrospective multicentre study (n=72) compared intravenous and subcutaneous esketamine protocols for treatment-resistant depression in routine clinical care. Intravenous treatment showed a more favourable respon...